Balixafortide TFA

Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC 50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7 . Balixafortide TFA blocks β-arreAppearance:SolidIC50& Target:CXCR4 <10 nM (IC 50 )In Vitro:Balixafortide potently inhibits pERK / pAKT signaling in the lymphoma lines Namalwa (IC 50 < 200 nM) and Jurkat (IC 50 < 400 nM). Balixafortide efficiently blocks SDF-1 dependent chemotaxis of MDA MB 231 breast cancer cells (IC 50 < 20 nM), Namalwa and JuIn Vivo:Balixafortide is optimized for favorable mouse absorption, distribution, metabolism and excretion (ADME) properties with balanced plasma protein binding, greater plasma and microsomal stability. MCE has not independently confirmed the accuracy of theBiological Activity:Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC 50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7 . Balixafortide TFA blocks β-arre

Specifictaions: Moligand™, ≥98%

MDL Number: C84H118N24O21S2(free base)

Molecular Formula: 1864.11(free base)